nicotine 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definitionDrug idCAS RN
1920 54-11-5

Description:

MoleculeDescription

Molfile Inchi Smiles

Synonyms:

  • nicotine
  • L-Nicotine
  • (S)-Nicotine
  • (-)-Nicotine
  • nicotine bitartrate anhydrous
  • nicotine polacrilex
Devices or delivery systems used to aid in ending a TOBACCO habit.
  • Molecular weight: 162.24
  • Formula: C10H14N2
  • CLOGP: 0.88
  • LIPINSKI: 0
  • HAC: 2
  • HDO: 0
  • TPSA: 16.13
  • ALOGS: -0.24
  • ROTB: 1
  • Status: OFP
    • Legend:
    OFP - off patent
    OFM - off market
    ONP - on patent

Drug dosage:

DoseUnitRoute
30 mg Chewing gum
60 mg Inhal
30 mg N
30 mg SL
14 mg TD

ADMET properties:

PropertyValueReference
BDDCS (Biopharmaceutical Drug Disposition Classification System) 1 Benet LZ, Broccatelli F, Oprea TI
EoM (Fraction excreted unchanged in urine) 16.70 % Benet LZ, Broccatelli F, Oprea TI
MRTD (Maximum Recommended Therapeutic Daily Dose) 3.52 µM/kg/day Contrera JF, Matthews EJ, Kruhlak NL, Benz RD
BA (Bioavailability) 30 % Kim MT, Sedykh A, Chakravarti SK, Saiakhov RD, Zhu H
Vd (Volume of distribution) 2.60 L/kg Lombardo F, Berellini G, Obach RS
CL (Clearance) 18 mL/min/kg Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma) 0.95 % Lombardo F, Berellini G, Obach RS
t_half (Half-life) 2 hours Lombardo F, Berellini G, Obach RS

Approvals:

DateAgencyCompanyOrphan
Nov. 7, 1991 FDA SANOFI AVENTIS US

FDA Adverse Event Reporting System (Female)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Macular degeneration 647.67 13.56 233 16092 18675 56257067
Nicotine dependence 581.78 13.56 110 16215 598 56275144
Drug withdrawal syndrome neonatal 284.97 13.56 74 16251 1942 56273800
Drug dependence 250.86 13.56 125 16200 22408 56253334
Foetal exposure during pregnancy 211.04 13.56 128 16197 33695 56242047
Incorrect product administration duration 205.95 13.56 86 16239 10240 56265502
Premature delivery 204.64 13.56 116 16209 26944 56248798
Product adhesion issue 186.79 13.56 64 16261 4419 56271323
Overdose 180.56 13.56 186 16139 105644 56170098
Maternal exposure during pregnancy 113.92 13.56 200 16125 189353 56086389
Myocardial stunning 101.51 13.56 20 16305 139 56275603
Rheumatoid arthritis 84.95 13.56 7 16318 382597 55893145
Application site erythema 84.00 13.56 36 16289 4564 56271178
Intentional product misuse 83.17 13.56 88 16237 51416 56224326
Jaundice neonatal 81.24 13.56 23 16302 840 56274902
Dependence 81.20 13.56 28 16297 1969 56273773
Accidental overdose 80.24 13.56 58 16267 20403 56255339
Application site pruritus 73.42 13.56 31 16294 3788 56271954
Drug abuse 71.55 13.56 93 16232 67517 56208225
Poor feeding infant 70.05 13.56 16 16309 240 56275502
Necrosis ischaemic 68.92 13.56 20 16305 799 56274943
Product quality issue 67.48 13.56 63 16262 31673 56244069
Rhesus incompatibility 67.21 13.56 13 16312 81 56275661
Rib deformity 66.90 13.56 15 16310 206 56275536
Premature baby 65.37 13.56 50 16275 19155 56256587
Chronic sinusitis 60.83 13.56 35 16290 8343 56267399
Tobacco abuse 59.57 13.56 17 16308 639 56275103
Exposure during pregnancy 58.64 13.56 125 16200 136217 56139525
Pneumonia streptococcal 58.44 13.56 21 16304 1667 56274075
Oligohydramnios 54.38 13.56 29 16296 5965 56269777
Beta haemolytic streptococcal infection 52.46 13.56 20 16305 1874 56273868
Paraesthesia oral 52.23 13.56 39 16286 14410 56261332
Chronic obstructive pulmonary disease 50.17 13.56 72 16253 57343 56218399
Maternal exposure during breast feeding 48.90 13.56 23 16302 3624 56272118
Low birth weight baby 45.05 13.56 26 16299 6232 56269510
Procedural pain 41.90 13.56 36 16289 16235 56259507
Nasal obstruction 41.20 13.56 15 16310 1236 56274506
Arthropathy 40.91 13.56 5 16320 200270 56075472
Alopecia 40.87 13.56 17 16308 293441 55982301
Reversible airways obstruction 39.72 13.56 15 16310 1369 56274373
Treatment noncompliance 39.46 13.56 48 16277 32575 56243167
Exposure via breast milk 39.19 13.56 16 16309 1796 56273946
Throat clearing 38.26 13.56 15 16310 1515 56274227
Application site rash 37.87 13.56 17 16308 2406 56273336
Application site reaction 37.40 13.56 12 16313 674 56275068
Congenital tricuspid valve incompetence 36.83 13.56 8 16317 94 56275648
Anxiety 34.78 13.56 129 16196 193043 56082699
Congenital pulmonary hypertension 34.55 13.56 7 16318 57 56275685
Joint swelling 34.04 13.56 21 16304 289779 55985963
Systemic lupus erythematosus 33.31 13.56 6 16319 180072 56095670
Substance abuse 33.10 13.56 19 16306 4506 56271236
Drug ineffective 32.02 13.56 406 15919 918583 55357159
Treatment failure 30.82 13.56 6 16319 170386 56105356
Therapeutic product effect decreased 30.58 13.56 6 16319 169446 56106296
Toxicity to various agents 30.17 13.56 137 16188 224427 56051315
Developmental hip dysplasia 29.81 13.56 12 16313 1299 56274443
Premature separation of placenta 29.60 13.56 13 16312 1747 56273995
Sputum purulent 29.33 13.56 11 16314 985 56274757
Arthralgia 29.14 13.56 64 16261 501605 55774137
Fatigue 29.13 13.56 124 16201 788428 55487314
Reversible cerebral vasoconstriction syndrome 28.85 13.56 14 16311 2363 56273379
Caesarean section 28.66 13.56 29 16296 16062 56259680
Maternal drugs affecting foetus 28.49 13.56 18 16307 5075 56270667
Agitation neonatal 28.25 13.56 9 16316 494 56275248
Drug intolerance 27.39 13.56 22 16303 264796 56010946
Dysmetropsia 27.28 13.56 6 16319 75 56275667
Contraindicated product administered 27.22 13.56 10 16315 186276 56089466
Application site irritation 27.13 13.56 12 16313 1640 56274102
Secondary immunodeficiency 26.99 13.56 11 16314 1229 56274513
Axonal neuropathy 26.15 13.56 10 16315 945 56274797
Loss of proprioception 25.91 13.56 8 16317 396 56275346
Full blood count abnormal 25.81 13.56 35 16290 26427 56249315
Xanthogranuloma 24.92 13.56 4 16321 6 56275736
Chest X-ray abnormal 24.32 13.56 15 16310 4055 56271687
Abnormal dreams 24.13 13.56 21 16304 9628 56266114
Application site swelling 23.43 13.56 8 16317 546 56275196
Symphysiolysis 23.30 13.56 4 16321 11 56275731
Irritability 22.81 13.56 35 16290 29553 56246189
Glossodynia 22.58 13.56 8 16317 152450 56123292
Application site dermatitis 22.55 13.56 6 16319 173 56275569
Premature labour 22.24 13.56 22 16303 11860 56263882
Abortion induced 22.15 13.56 20 16305 9625 56266117
Discomfort 21.76 13.56 7 16318 141754 56133988
Rhinitis 21.49 13.56 19 16306 8897 56266845
Drug screen positive 21.29 13.56 13 16312 3451 56272291
Sneezing 20.63 13.56 24 16301 15536 56260206
Infection 20.23 13.56 17 16308 200189 56075553
Musculoskeletal stiffness 20.19 13.56 10 16315 155997 56119745
Respiratory failure 20.11 13.56 67 16258 94995 56180747
Swelling 20.07 13.56 24 16301 239747 56035995
Abdominal discomfort 19.94 13.56 31 16294 277243 55998499
Cardiac death 19.76 13.56 7 16318 533 56275209
Application site vesicles 19.51 13.56 9 16316 1356 56274386
False positive investigation result 19.49 13.56 7 16318 555 56275187
Wound 19.36 13.56 8 16317 138796 56136946
Hepatic enzyme increased 19.31 13.56 13 16312 171371 56104371
Withdrawal syndrome 18.89 13.56 25 16300 18437 56257305
Upper-airway cough syndrome 18.65 13.56 18 16307 9420 56266322
Therapeutic product effect incomplete 18.38 13.56 70 16255 105961 56169781
Oophoritis 18.34 13.56 4 16321 48 56275694
Pre-eclampsia 18.32 13.56 17 16308 8469 56267273
Suicidal ideation 18.28 13.56 47 16278 57695 56218047
Nightmare 17.55 13.56 23 16302 16803 56258939
Completed suicide 17.46 13.56 81 16244 133752 56141990
Application site pain 17.42 13.56 12 16313 3908 56271834
Megacolon 17.38 13.56 9 16316 1742 56274000
Prinzmetal angina 17.38 13.56 7 16318 759 56274983
Application site burn 17.19 13.56 7 16318 780 56274962
Selective eating disorder 16.67 13.56 9 16316 1895 56273847
Application site scar 16.65 13.56 5 16320 225 56275517
Nasopharyngitis 16.56 13.56 24 16301 220935 56054807
Loss of consciousness 16.40 13.56 69 16256 109280 56166462
Condition aggravated 16.14 13.56 49 16276 344849 55930893
Tobacco poisoning 15.94 13.56 4 16321 91 56275651
Impaired healing 15.82 13.56 3 16322 86838 56188904
Drug abuser 15.73 13.56 10 16315 2849 56272893
Off label use 15.61 13.56 96 16229 556084 55719658
Pain 15.41 13.56 121 16204 663063 55612679
Antipsychotic drug level decreased 15.12 13.56 5 16320 309 56275433
Diarrhoea 15.07 13.56 116 16209 638391 55637351
Patent ductus arteriosus 15.03 13.56 11 16314 3940 56271802
Mobility decreased 14.99 13.56 5 16320 98986 56176756
Foetal growth restriction 14.90 13.56 14 16311 7085 56268657
Peripheral swelling 14.37 13.56 29 16296 234697 56041045
Tobacco interaction 14.16 13.56 3 16322 31 56275711
Nervousness 14.09 13.56 28 16297 28987 56246755
Blister 14.05 13.56 7 16318 108880 56166862
Plethysmography 13.99 13.56 3 16322 33 56275709
Foetal distress syndrome 13.88 13.56 7 16318 1283 56274459
Drug withdrawal syndrome 13.84 13.56 26 16299 25831 56249911
Sleep disorder due to a general medical condition 13.72 13.56 15 16310 9075 56266667
Gastric dilatation 13.70 13.56 6 16319 801 56274941
Hepatitis C 13.65 13.56 12 16313 5574 56270168
Application site warmth 13.61 13.56 4 16321 167 56275575

FDA Adverse Event Reporting System (Male)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 379.79 13.53 77 12942 423 31683902
Drug withdrawal syndrome neonatal 300.93 13.53 94 12925 3398 31680927
Drug dependence 274.76 13.53 149 12870 22430 31661895
Incorrect product administration duration 227.02 13.53 80 12939 4222 31680103
Foetal exposure during pregnancy 209.28 13.53 156 12863 40720 31643605
Intentional product misuse 159.70 13.53 129 12890 37822 31646503
Overdose 138.47 13.53 172 12847 84492 31599833
Accidental overdose 133.59 13.53 87 12932 18263 31666062
Product adhesion issue 118.69 13.53 38 12981 1487 31682838
Maternal exposure during breast feeding 101.95 13.53 34 12985 1515 31682810
Premature baby 99.20 13.53 72 12947 17994 31666331
Dependence 84.06 13.53 27 12992 1067 31683258
Low birth weight baby 76.43 13.53 43 12976 6927 31677398
Jaundice neonatal 64.10 13.53 23 12996 1277 31683048
Alcohol abuse 63.56 13.53 33 12986 4531 31679794
Foetal disorder 62.27 13.53 20 12999 790 31683535
Toxicity to various agents 60.03 13.53 187 12832 181300 31503025
Exposure via breast milk 59.52 13.53 24 12995 1836 31682489
Tobacco poisoning 58.83 13.53 10 13009 15 31684310
Neutropenia neonatal 53.11 13.53 17 13002 664 31683661
Drug screen positive 51.21 13.53 27 12992 3825 31680500
Poor feeding infant 50.37 13.53 15 13004 459 31683866
Tremor neonatal 48.65 13.53 14 13005 379 31683946
Drug abuser 48.21 13.53 26 12993 3854 31680471
Alcohol interaction 44.18 13.53 22 12997 2767 31681558
Tobacco abuse 43.77 13.53 13 13006 394 31683931
Agitation neonatal 38.23 13.53 15 13004 1068 31683257
Breech presentation 36.23 13.53 9 13010 136 31684189
Body temperature abnormal 35.65 13.53 12 13007 550 31683775
Application site pruritus 35.46 13.53 15 13004 1295 31683030
Foetal distress syndrome 35.19 13.53 14 13005 1034 31683291
Substance abuse 33.63 13.53 26 12993 7132 31677193
Finnegan score increased 32.48 13.53 6 13013 18 31684307
Drug use disorder 31.72 13.53 20 12999 3963 31680362
Withdrawal syndrome 31.59 13.53 31 12988 11686 31672639
Application site erythema 31.39 13.53 16 13003 2113 31682212
Drug withdrawal syndrome 30.39 13.53 38 12981 18712 31665613
Infant irritability 29.89 13.53 6 13013 31 31684294
Drug abuse 28.51 13.53 90 12929 87668 31596657
Laryngeal dysplasia 27.19 13.53 4 13015 0 31684325
Application site reaction 26.89 13.53 9 13010 405 31683920
Off label use 26.79 13.53 65 12954 347209 31337116
Product quality issue 26.67 13.53 33 12986 16078 31668247
Schizophrenia 26.16 13.53 27 12992 10803 31673522
Infective exacerbation of chronic obstructive airways disease 25.66 13.53 13 13006 1695 31682630
Regurgitation 25.46 13.53 12 13007 1337 31682988
Venolymphatic malformation 25.21 13.53 5 13014 24 31684301
Tobacco user 24.43 13.53 9 13010 539 31683786
Product availability issue 24.40 13.53 12 13007 1469 31682856
Tachycardia 23.69 13.53 77 12942 76130 31608195
Floppy infant 23.01 13.53 6 13013 111 31684214
Treatment noncompliance 22.57 13.53 39 12980 25645 31658680
Oropharyngeal discomfort 22.47 13.53 14 13005 2717 31681608
Vitamin B12 deficiency 21.55 13.53 15 13004 3504 31680821
Application site rash 21.39 13.53 9 13010 767 31683558
Acne infantile 20.04 13.53 5 13014 77 31684248
Diarrhoea 19.97 13.53 76 12943 352333 31331992
Application site scar 19.56 13.53 4 13015 23 31684302
Renal hypoplasia 19.47 13.53 5 13014 87 31684238
Neonatal hypoxia 19.41 13.53 7 13012 394 31683931
Euphoric mood 19.13 13.53 16 13003 4904 31679421
Palpitations 18.87 13.53 43 12976 34540 31649785
Insomnia 18.82 13.53 83 12936 94753 31589572
Potentiating drug interaction 18.11 13.53 15 13004 4538 31679787
Pulmonary valve stenosis congenital 17.42 13.53 5 13014 134 31684191
Application site vesicles 17.30 13.53 7 13012 540 31683785
Antipsychotic drug level increased 17.21 13.53 13 13006 3445 31680880
Nightmare 17.17 13.53 23 12996 12114 31672211
Renal impairment 17.14 13.53 7 13012 86342 31597983
Weight decrease neonatal 16.79 13.53 6 13013 329 31683996
Adjustment disorder with mixed anxiety and depressed mood 16.79 13.53 3 13016 7 31684318
Anxiety 16.08 13.53 77 12942 90956 31593369
Emphysema 15.95 13.53 19 13000 8899 31675426
Breathing-related sleep disorder 15.93 13.53 5 13014 183 31684142
Necrotising ulcerative gingivostomatitis 15.50 13.53 4 13015 71 31684254
Myoclonic epilepsy 15.36 13.53 8 13011 1104 31683221
Application site urticaria 15.34 13.53 4 13015 74 31684251
Agitation 15.29 13.53 53 12966 54116 31630209
Hypersensitivity 15.27 13.53 54 12965 55689 31628636
Eructation 15.04 13.53 13 13006 4166 31680159
Application site discolouration 15.03 13.53 5 13014 221 31684104
Drug tolerance increased 14.86 13.53 6 13013 460 31683865
Neonatal disorder 14.69 13.53 7 13012 799 31683526
Application site pain 14.47 13.53 9 13010 1740 31682585
Death 14.43 13.53 88 12931 360481 31323844
Chest pain 13.98 13.53 89 12930 116868 31567457
Maternal drugs affecting foetus 13.76 13.53 12 13007 3891 31680434

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event termLikelihood ratioLikelihood ratio thresholdPatients taking drug having adverse eventPatients taking drug not having adverse eventPatients not taking drug having adverse eventPatients not taking drug not having adverse event
Nicotine dependence 598.18 12.59 118 22528 741 70905057
Drug dependence 472.75 12.59 233 22413 37088 70868710
Incorrect product administration duration 341.75 12.59 129 22517 10695 70895103
Overdose 265.45 12.59 298 22348 169447 70736351
Accidental overdose 219.97 12.59 138 22508 34983 70870815
Intentional product misuse 154.69 12.59 157 22489 79438 70826360
Application site erythema 98.95 12.59 42 22604 4719 70901079
Myocardial stunning 95.72 12.59 20 22626 173 70905625
Application site pruritus 92.62 12.59 37 22609 3564 70902234
Product adhesion issue 86.64 12.59 32 22614 2492 70903306
Toxicity to various agents 86.34 12.59 293 22353 381879 70523919
Drug abuse 83.25 12.59 160 22486 147096 70758702
Rheumatoid arthritis 76.75 12.59 4 22642 291801 70613997
Alcohol abuse 70.93 12.59 34 22612 5073 70900725
Substance abuse 70.09 12.59 42 22604 9795 70896003
Necrosis ischaemic 63.00 12.59 20 22626 984 70904814
Tobacco abuse 61.08 12.59 19 22627 874 70904924
Drug abuser 60.73 12.59 32 22614 5832 70899966
Dependence 60.43 12.59 24 22622 2276 70903522
Rib deformity 57.83 12.59 13 22633 163 70905635
Tobacco poisoning 57.31 12.59 12 22634 105 70905693
Product quality issue 53.41 12.59 57 22589 30504 70875294
Beta haemolytic streptococcal infection 53.34 12.59 21 22625 1946 70903852
Macular degeneration 53.26 12.59 32 22614 7496 70898302
Chronic sinusitis 52.35 12.59 33 22613 8418 70897380
Application site reaction 52.05 12.59 16 22630 707 70905091
Pneumonia streptococcal 51.91 12.59 22 22624 2461 70903337
Application site rash 46.03 12.59 19 22627 1990 70903808
Chronic obstructive pulmonary disease 45.85 12.59 86 22560 77555 70828243
Product availability issue 44.85 12.59 21 22625 2973 70902825
Paraesthesia oral 42.58 12.59 37 22609 15380 70890418
Alcohol interaction 41.51 12.59 23 22623 4630 70901168
Drug use disorder 41.14 12.59 28 22618 8123 70897675
Premature delivery 39.48 12.59 41 22605 21263 70884535
Application site irritation 39.46 12.59 16 22630 1601 70904197
Withdrawal syndrome 39.26 12.59 44 22602 24860 70880938
Drug screen positive 39.20 12.59 24 22622 5816 70899982
Drug withdrawal syndrome 38.77 12.59 50 22596 32665 70873133
Application site pain 37.20 12.59 21 22625 4381 70901417
Anxiety 37.16 12.59 154 22492 220176 70685622
Application site scar 35.92 12.59 9 22637 184 70905614
Throat clearing 35.24 12.59 15 22631 1696 70904102
Drug intolerance 35.19 12.59 14 22632 225673 70680125
Treatment noncompliance 33.16 12.59 56 22590 46518 70859280
Procedural pain 32.19 12.59 34 22612 17975 70887823
Loss of consciousness 32.10 12.59 116 22530 155600 70750198
Therapeutic product effect decreased 31.96 12.59 4 22642 143014 70762784
Euphoric mood 30.87 12.59 22 22624 6867 70898931
Nasal obstruction 29.61 12.59 13 22633 1584 70904214
Reversible airways obstruction 29.54 12.59 13 22633 1594 70904204
Reversible cerebral vasoconstriction syndrome 28.79 12.59 15 22631 2670 70903128
Off label use 28.10 12.59 132 22514 742928 70162870
Tachycardia 26.86 12.59 111 22535 158435 70747363
Infective exacerbation of chronic obstructive airways disease 26.85 12.59 14 22632 2497 70903301
Alopecia 26.81 12.59 15 22631 198475 70707323
Schizoaffective disorder 26.68 12.59 13 22633 2010 70903788
Maternal drugs affecting foetus 26.08 12.59 12 22634 1632 70904166
Dysmetropsia 26.01 12.59 6 22640 85 70905713
Arthropathy 25.63 12.59 8 22638 150049 70755749
Application site vesicles 25.20 12.59 11 22635 1322 70904476
Arthralgia 25.06 12.59 80 22566 503310 70402488
Nightmare 24.91 12.59 33 22613 22123 70883675
Application site urticaria 24.57 12.59 7 22639 237 70905561
Joint swelling 24.30 12.59 27 22619 253184 70652614
Body temperature abnormal 24.25 12.59 12 22634 1917 70903881
Mental status changes 23.51 12.59 58 22588 63043 70842755
Emphysema 22.70 12.59 26 22620 15034 70890764
Sputum purulent 22.54 12.59 10 22636 1250 70904548
Regurgitation 22.48 12.59 12 22634 2244 70903554
Unresponsive to stimuli 21.80 12.59 50 22596 51881 70853917
Application site dermatitis 21.79 12.59 6 22640 179 70905619
Diarrhoea 21.63 12.59 154 22492 783187 70122611
Exposure during pregnancy 21.26 12.59 69 22577 87648 70818150
Renal impairment 20.73 12.59 10 22636 143927 70761871
Application site discolouration 20.59 12.59 8 22638 716 70905082
Maternal exposure during pregnancy 20.51 12.59 82 22564 115263 70790535
Loss of proprioception 20.47 12.59 8 22638 727 70905071
Schizophrenia 20.45 12.59 26 22620 16742 70889056
Fatigue 19.97 12.59 168 22478 824151 70081647
Vitamin B12 deficiency 19.95 12.59 16 22630 5956 70899842
Infection 19.65 12.59 23 22623 210762 70695036
Arteriosclerosis coronary artery 19.55 12.59 25 22621 16190 70889608
Full blood count abnormal 19.34 12.59 37 22609 33841 70871957
Pulmonary oedema 19.29 12.59 64 22582 82214 70823584
Palpitations 19.11 12.59 78 22568 110675 70795123
Oophoritis 18.90 12.59 4 22642 37 70905761
Tobacco withdrawal symptoms 18.61 12.59 3 22643 4 70905794
Axonal neuropathy 18.42 12.59 10 22636 1934 70903864
Systemic lupus erythematosus 18.19 12.59 5 22641 101897 70803901
Chest pain 17.70 12.59 139 22507 251121 70654677
Derealisation 17.68 12.59 9 22637 1527 70904271
Oropharyngeal discomfort 17.62 12.59 15 22631 6064 70899734
Application site swelling 17.51 12.59 7 22639 675 70905123
Drug ineffective 17.16 12.59 205 22441 939547 69966251
Suicidal ideation 17.09 12.59 55 22591 69541 70836257
Disease progression 16.98 12.59 15 22631 156657 70749141
Nasopharyngitis 16.96 12.59 28 22618 222178 70683620
Hepatocellular injury 16.78 12.59 42 22604 46049 70859749
Intentional overdose 16.72 12.59 69 22577 98366 70807432
Nervousness 16.56 12.59 33 22613 31087 70874711
Chest discomfort 16.49 12.59 81 22565 124300 70781498
Breathing-related sleep disorder 16.40 12.59 5 22641 215 70905583
Foetal distress syndrome 16.31 12.59 6 22640 462 70905336
Tobacco interaction 16.24 12.59 4 22642 76 70905722
Xanthogranuloma 15.95 12.59 4 22642 82 70905716
Hepatic enzyme increased 15.88 12.59 16 22630 156974 70748824
Poor quality product administered 15.77 12.59 11 22635 3320 70902478
Delirium 15.71 12.59 56 22590 74558 70831240
Gastrointestinal disorder 15.68 12.59 7 22639 105420 70800378
False positive investigation result 15.65 12.59 7 22639 891 70904907
Potentiating drug interaction 15.64 12.59 16 22630 8148 70897650
Myocarditis 15.28 12.59 24 22622 18769 70887029
Cardiac death 15.19 12.59 8 22638 1455 70904343
Irritability 15.16 12.59 36 22610 38189 70867609
Secondary immunodeficiency 14.76 12.59 10 22636 2879 70902919
Hypoxia 14.74 12.59 64 22582 93280 70812518
Abortion induced 14.58 12.59 14 22632 6611 70899187
Impaired healing 14.55 12.59 3 22643 74371 70831427
Respiratory arrest 14.51 12.59 44 22602 53889 70851909
Treatment failure 14.23 12.59 15 22631 144127 70761671
Plasma cell myeloma 14.22 12.59 3 22643 73198 70832600
Hyperhidrosis 14.22 12.59 81 22565 131505 70774293
Accidental death 14.19 12.59 11 22635 3897 70901901
Premature labour 14.11 12.59 15 22631 7985 70897813
Neuropathy peripheral 13.93 12.59 12 22634 126884 70778914
Mental disorder 13.90 12.59 29 22617 28211 70877587
Premature separation of placenta 13.88 12.59 7 22639 1165 70904633
Plethysmography 13.71 12.59 3 22643 33 70905765
Myoclonic epilepsy 13.38 12.59 8 22638 1856 70903942
Psychotic disorder 13.35 12.59 34 22612 37667 70868131
Dyspepsia 13.25 12.59 60 22586 89017 70816781
Arteriosclerosis 13.18 12.59 21 22625 16617 70889181
Contusion 13.00 12.59 13 22633 128023 70777775
Pre-eclampsia 12.96 12.59 13 22633 6472 70899326
Application site warmth 12.92 12.59 4 22642 181 70905617
Non-small cell lung cancer stage IIIB 12.91 12.59 3 22643 44 70905754
COVID-19 12.88 12.59 9 22637 105748 70800050

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

SourceCodeDescription
ATC N07BA01 NERVOUS SYSTEM
OTHER NERVOUS SYSTEM DRUGS
DRUGS USED IN ADDICTIVE DISORDERS
Drugs used in nicotine dependence
FDA CS M0014836 Nicotine
MeSH PA D018678 Cholinergic Agents
MeSH PA D018679 Cholinergic Agonists
MeSH PA D005731 Ganglionic Stimulants
MeSH PA D018377 Neurotransmitter Agents
MeSH PA D018722 Nicotinic Agonists
MeSH PA D018373 Peripheral Nervous System Agents
MeSH PA D000077444 Smoking Cessation Agents
FDA EPC N0000175706 Cholinergic Nicotinic Agonist
CHEBI has role CHEBI:22917 botanical insecticides
CHEBI has role CHEBI:35471 psychotropic drugs
CHEBI has role CHEBI:35474 anti-anxiety agents
CHEBI has role CHEBI:35703 Xenobiotic
CHEBI has role CHEBI:47958 muscarinic agonists
CHEBI has role CHEBI:49110 peripheral nervous system drugs
CHEBI has role CHEBI:50846 Immunologic factor
CHEBI has role CHEBI:50905 teratogeno
CHEBI has role CHEBI:50910 agente neurotoxico
CHEBI has role CHEBI:52290 mitogens
CHEBI has role CHEBI:59163 biological marker
CHEBI has role CHEBI:76924 plant metabolites

Drug Use | Suggest Off label Use Form| |View source of the data|

DiseaseRelationSNOMED_IDDOID
Nicotine dependence indication 56294008 DOID:0050742
Smoking cessation assistance indication 384742004
Pellagra indication 418186002 DOID:8457
Niacin deficiency indication 418279001
Nicotine Withdrawal Symptoms indication
Hyperlipidemia off-label use 55822004 DOID:1168
Hypophosphatemia contraindication 4996001
Alcoholism contraindication 7200002
Peptic ulcer contraindication 13200003 DOID:750
Esophagitis contraindication 16761005 DOID:11963
Myocardial infarction contraindication 22298006 DOID:5844
Hyperthyroidism contraindication 34486009 DOID:7998
Temporomandibular joint disorder contraindication 41888000
Low blood pressure contraindication 45007003
Diabetes mellitus type 1 contraindication 46635009 DOID:9744
Thromboangiitis obliterans contraindication 52403007 DOID:12918
Blood coagulation disorder contraindication 64779008 DOID:1247
Diabetes mellitus contraindication 73211009 DOID:9351
Hyperglycemia contraindication 80394007 DOID:4195
Prinzmetal angina contraindication 87343002
Gout contraindication 90560007 DOID:13189
Magnetic resonance imaging contraindication 113091000
Liver function tests abnormal contraindication 166603001
Angina pectoris contraindication 194828000
Arterial hemorrhage contraindication 234003006
Disease of liver contraindication 235856003 DOID:409
Raynaud's phenomenon contraindication 266261006
Pregnancy, function contraindication 289908002
Thrombocytopenic disorder contraindication 302215000 DOID:1588
Pheochromocytoma contraindication 302835009
Acute coronary syndrome contraindication 394659003
Pharyngitis contraindication 405737000 DOID:2275
Disorder of coronary artery contraindication 414024009
Myocardial infarction in recovery phase contraindication 418044006
Hypertensive urgency contraindication 443482000
Life-Threatening Cardiac Arrhythmias contraindication




🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation levelDissociation constantType (acidic/basic)
pKa1 9.05 Basic
pKa2 3.14 Basic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

TargetClassPharosUniProtActionTypeActivity value
(-log[M])		Mechanism
action		Bioact sourceMoA source
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel AGONIST Ki 8.56 WOMBAT-PK CHEMBL
Potassium voltage-gated channel subfamily D member 3 Ion channel IC50 7.40 WOMBAT-PK
Cytochrome P450 2A6 Enzyme IC50 5.36 WOMBAT-PK
Transient receptor potential cation channel subfamily A member 1 Ion channel ACTIVATOR EC50 4.80 IUPHAR
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 5.95 WOMBAT-PK
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 7.85 WOMBAT-PK
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 7.64 CHEMBL
Serotonin 3 (5-HT3) receptor Ion channel Ki 4.15 CHEMBL
Acetylcholine receptor; alpha1/beta1/delta/gamma Ion channel Ki 5.83 CHEMBL
Neuronal acetylcholine receptor; alpha3/alpha6/beta2/beta3 Ion channel IC50 7.07 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.68 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel IC50 7.35 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 5.39 WOMBAT-PK
Acetylcholine-binding protein Unclassified Ki 7.20 CHEMBL
Acetylcholine receptor subunit delta Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 9.03 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.89 CHEMBL
Neuronal acetylcholine receptor subunit alpha-7 Ion channel Ki 6.61 CHEMBL
Neuronal acetylcholine receptor subunit alpha-9 Ion channel Kd 8.30 CHEMBL
Neuronal acetylcholine receptor subunit beta-4 Ion channel Ki 7.14 CHEMBL
Neuronal acetylcholine receptor subunit alpha-3 Ion channel Ki 7.33 CHEMBL
Neuronal acetylcholine receptor subunit alpha-2 Ion channel Ki 7.92 CHEMBL
Soluble acetylcholine receptor Unclassified Ki 7.52 CHEMBL
Acetylcholine receptor subunit alpha Ion channel IC50 4.64 CHEMBL
Lycopene cyclase Enzyme IC50 5.32 CHEMBL
Nicotinic acetylcholine receptor alpha 5 subunit Ion channel Ki 5.61 CHEMBL
Acetylcholine receptor subunit beta-like 2 Ion channel Ki 5.57 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel Ki 8.72 CHEMBL
Neuronal acetylcholine receptor subunit alpha-4 Ion channel IC50 8.15 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta2 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta2 Ion channel Ki 9 CHEMBL
Neuronal acetylcholine receptor; alpha3/beta4 Ion channel Ki 6.70 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta2 Ion channel Kd 9.40 CHEMBL
Neuronal acetylcholine receptor; alpha4/beta4 Ion channel Ki 8.26 CHEMBL
Neuronal acetylcholine receptor Ion channel Kd 11 CHEMBL
Neuronal acetylcholine receptor; alpha2/beta4 Ion channel Ki 7.15 CHEMBL
Acetylcholine receptor Ion channel Ki 5.20 CHEMBL
Muscarinic acetylcholine receptor GPCR IC50 4.55 CHEMBL
Transient receptor potential cation channel subfamily A member 1 Ion channel EC50 5 CHEMBL
Potassium voltage-gated channel subfamily D member 3 Ion channel BLOCKER IC50 7.40 IUPHAR

External reference:

IDSource
4020286 VUID
N0000148163 NUI
D03365 KEGG_DRUG
4018610 VANDF
4020286 VANDF
C0028040 UMLSCUI
CHEBI:17688 CHEBI
NCT PDB_CHEM_ID
CHEMBL3 ChEMBL_ID
DB00184 DRUGBANK_ID
CHEMBL3989563 ChEMBL_ID
D009538 MESH_DESCRIPTOR_UI
89594 PUBCHEM_CID
2585 IUPHAR_LIGAND_ID
65-31-6 SECONDARY_CAS_RN
6M3C89ZY6R UNII
1306106 RXNORM
11529 MMSL
5173 MMSL
5174 MMSL
72003 MMSL
d00316 MMSL
001770 NDDF
003575 NDDF
323283001 SNOMEDCT_US
68540007 SNOMEDCT_US
77544001 SNOMEDCT_US
D061485 MESH_DESCRIPTOR_UI
CHEMBL1201536 ChEMBL_ID

Pharmaceutical products:

ProductCategoryIngredientsNDCFormQuantityRouteMarketingLabel
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5400 INHALANT 4 mg RESPIRATORY (INHALATION) NDA 29 sections
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5401 SPRAY, METERED 10 mg NASAL NDA 28 sections
Nicotrol HUMAN PRESCRIPTION DRUG LABEL 1 0009-5401 SPRAY, METERED 10 mg NASAL NDA 28 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0053 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0170 GUM, CHEWING 4 mg ORAL ANDA 15 sections
good sense nicotinemint HUMAN OTC DRUG LABEL 1 0113-0206 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0344 LOZENGE 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0422 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0456 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0532 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0704 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0713 GUM, CHEWING 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0734 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0749 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-0761 GUM, CHEWING 2 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0854 GUM, CHEWING 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-0873 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-0957 LOZENGE 4 mg ORAL ANDA 15 sections
Good Sense Nicotine HUMAN OTC DRUG LABEL 1 0113-1125 LOZENGE 2 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1190 LOZENGE 4 mg ORAL ANDA 15 sections
good sense nicotine HUMAN OTC DRUG LABEL 1 0113-1352 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7007 LOZENGE 4 mg ORAL ANDA 14 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7008 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7029 GUM, CHEWING 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7124 LOZENGE 2 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7170 GUM, CHEWING 4 mg ORAL ANDA 15 sections
basic care nicotine HUMAN OTC DRUG LABEL 1 0113-7190 LOZENGE 4 mg ORAL ANDA 15 sections
Basic Care nicotine HUMAN OTC DRUG LABEL 1 0113-7201 LOZENGE 2 mg ORAL ANDA 14 sections
Basic Care nicotine HUMAN OTC DRUG LABEL 1 0113-7203 LOZENGE 4 mg ORAL ANDA 14 sections